All You Need to Know About Regeneron (REGN) Rating Upgrade to BuyZacks Investment Research • 04/06/26
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health SolutionsGlobeNewsWire • 04/02/26
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health SolutionsPRNewsWire • 04/02/26
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)GlobeNewsWire • 04/02/26
REGN Soars 28.9% in Six Months: Is There More Upside Potential in 2026?Zacks Investment Research • 03/25/26
Press Release: Sanofi and Regeneron's Dupixent approved in Japan as the first targeted medicine to treat adults with bullous pemphigoidGlobeNewsWire • 03/24/26
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)GlobeNewsWire • 03/24/26
In 2036, Investors Will Regret Not Loading Up on This Multibagger in the MakingThe Motley Fool • 03/12/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Leerink Global Healthcare Conference 2026 TranscriptSeeking Alpha • 03/11/26
Regeneron Science Talent Search 2026 Recognizes America's Top Young Scientists, Awarding More Than $1.8 Million to High School Seniors for Innovative Research in Computational Mathematics, Neural Science, and Blood Cancer TreatmentGlobeNewsWire • 03/11/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Barclays 28th Annual Global Healthcare Conference TranscriptSeeking Alpha • 03/10/26
Regeneron Pharmaceuticals, Inc. (REGN) Presents at TD Cowen 46th Annual Health Care Conference TranscriptSeeking Alpha • 03/04/26
REGN & SNY's Dupixent Gets CHMP Nod for Pediatric Use in UrticariaZacks Investment Research • 03/02/26
Press Release: Sanofi and Regeneron's Dupixent recommended for EU approval to treat chronic spontaneous urticaria in young children with ongoing symptoms despite treatmentGlobeNewsWire • 02/27/26
Dupixent® (dupilumab) Recommended for EU Approval to Treat Chronic Spontaneous Urticaria (CSU) in Young Children with Ongoing Symptoms Despite TreatmentGlobeNewsWire • 02/27/26